Daniel Meling
MSc researcher affiliated with the Psychedelic Research & Therapy Development group at the University of Zurich / Psychiatric University Clinic Zurich
Data updated
Research Footprint
Daniel Meling appears in 9 tracked papers (2024–2026), most studied alongside Ayahuasca, DMT and Placebo, across Healthy Volunteers, Depressive Disorders and Neuroimaging & Brain Measures.
Most-cited paper: Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression (26 citations).
Frequent co-authors: Milan Scheidegger, Dominik Dornbierer and Anne Aicher.
Background & Research
Daniel Meling is a researcher working in psychedelic and contemplative science, with affiliations in psychiatry and psychosomatic medicine in Zurich and Freiburg. His work spans randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and fMRI research on ayahuasca-inspired DMT/harmine formulations in mindfulness and meditation settings. He also publishes on psychedelics, meditation, and consciousness from an enactive/phenomenological perspective.
Key Impact
He is a recurring author on clinical and neuroimaging studies of DMT/harmine and meditation, contributing to some of the most visible contemporary psychedelic-mindfulness research.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Daniel Meling is associated with.
Psychiatric University Hospital, Zurich
The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →